. 👉 Strong resumes feel like protection against uncertainty. What Survival Traits Look Like in Real Biotech Work 👉 When founders start paying attention, they realize In teams working on complex biology like GPCR targets, this kind of drift is not unusual. matter in early-stage biotech environments. 1️⃣ How candidates describe moments without clear answers: Listen

Complexity feels like progress. At this stage, failure does not look like failure. It looks like motion. Additional data feels like risk reduction, even when it does not change the strategic picture. Teams are no longer sure what success looks like. 👉 No single decision breaks the company, but the absence business reality. ✅ At its core, this is what a functional strategy provides: 1️⃣ Clear priorities that limit

Slides list filings and dates, but do not explain how those rights support the fundraising narrative control that feel unclear or constrained This gap appears most often in academic spinouts, but it is not limited Typical problem areas include: 👉 University licenses with complex or restrictive terms 👉 Unclear rights Founders are expected to show awareness of constraints and options ✅ Looking toward 2026, this trend is likely They can explain what the IP protects, where its limits are, and how that fits the company's direction

. 👉 What it usually looks like: Weekly priorities shift based on whoever raised the loudest concern. That’s the danger. 👉 From the inside, however, it creates a quiet drift: lots of activity, little compounding investor messaging drifts Timelines become aspirational rather than operational ✅ What “good” looks like teams working with partial context narrative inconsistency across stakeholders ✅ What “good” looks like , not momentum Scientific surprises hit harder because the system has no buffer ✅ What “good” looks like

Tracer concentration, receptor density, equilibrium assumptions, and ligand kinetics all influence whether Already available in Terry’s Corner: 30 in-depth lessons and 3 live AMAs  spanning binding, kinetics, probes, fluorescence-based assays, and why availability can matter as much as discovery itself. 🎧 Listen This year brought 20+ podcast episodes, 40% audience growth, and an 811% increase in new listeners. 👉 Access this week’s full Premium Edition here ➤ Voice of the Community “It’s like being at a GPCR

. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. in real life: Meetings end with explanations, not decisions BD calls “went great,” but nothing moves From the outside, it looks like ambiguity. Strategic Takeaway - Why Traction Slips Scientific isolation doesn’t feel like a mistake. It feels like focus.

JB short-circuits that anxiety with a single line he’s used for years: “Hi, I’m JB. His tools exist because he constantly asks: What limitation is chemistry solving here? What limitation is biology solving? For more insight and nuance, listen to the full episode with JB. If JB's story resonates 🎧 Listen to part 1 of this series with Dr.

solid preclinical package, promising safety data, and a consistent in vivo proof-of-concept, it feels like Founders who prepare to present  often miss the deeper expectation: the FDA is not just listening, it What the FDA Is Actually Optimizing For 👉 Biotech teams often treat the FDA like an evaluator. In reality, the FDA acts more like a systems-level risk assessor . indication selection to study design, should be filtered through the question: “What would this look like

. 👉 Opening with mechanisms forces the listener to do all the work. . ✅ Start with relevance, not results. 2️⃣ Using buzzwords instead of clarity Words like “platform”, Your listener doesn’t want to be impressed. If your listener doesn’t know what to do next or who should be involved, the conversation stalls. ✅ A Make it easy for the listener to understand what sets your approach apart from existing solutions or

PAMs permit enhancement without replicating the liabilities of orthosteric agonists. Endogenous ligands remain part of the signaling equation, preserving physiological patterning. Efficacy is not a molecule-only attribute—it's a joint property of ligand and system. High-coupled systems inflate apparent efficacy; low-coupled systems expose its limits. Dr. One carries broad off-target risk; the other behaves more like a high-affinity ligand with slow dissociation

GPCR signaling wasn’t linear. It wasn’t clean. shaped his partnership with JB, the chemist who would eventually help his lab visualize receptors in living They think in functional groups, fluorophores, linkers, and binding pockets. Instead of forcing antibodies to do what they weren’t built for, JB’s group engineered fluorescent ligands The signaling didn’t line up. The knockout behaved differently than expected.

. 👉 We’re talking about the type of quiet misalignment that appears to be progress but feels like confusion You assume your cofounder sees the same finish line you do. When these lines blur, so do accountability and execution. 3️⃣ The third and hardest shift is restoring Realignment as a Growth Lever, Not Just a Fix 👉 Most founders treat alignment like a hygiene issue. But because it ensures everyone is solving the same problem. ✅ If your biotech startup feels like it’

 to remotely control GPCR signaling with light. This was the moment when photopharmacology felt like the future. The literature was buzzing. Live-tissue dynamics become guesswork. This accidental tool changed that. And importantly, they liked working together. Scientific progress is rarely linear. But depth compounds.

Meanwhile, researchers in the building across the way turned off the lights at 6 PM.  vs. cell lines. They start with people you actually like working with . GPCR–islet signaling links extended beyond classical ligand models.Collaboration and long-term persistence Should patients stay on incretin therapies for life?

David Hodson walks through how his team uses fluorescence tools and chemically engineered ligands to Fluorescent ligand engineering clarifies receptor behavior that cell lines can’t reveal. Who should listen Researchers navigating complex datasets, balancing innovation with assay rigor, or Listen to the episode ➤ Quick Links Assess GPCR Biased Signaling of Agonist How GPCR Collaboration Built With live GPCR University courses returning next year and platform capabilities expanding, Premium pricing

Most labs operated like small, competing startups. That gave them capabilities others couldn’t match — from receptor biosensor platforms to live-cell imaging Weekly seminars were mandatory but lightweight, designed to connect  rather than perform. It’s a competitive advantage. 🎧 Listen to the full episode:   Leadership, Luck, and GPCR Signaling 🔓

Just her, radioactive ligands, and steady hands. Every step felt like it could make or break the result, The pace and precision of GPCR research today — from high-throughput ligand screens to real-time signaling readouts — are built on the discipline Michelle’s path wasn’t linear. Her career didn’t follow a straight line — it zigzagged through long nights, and calculated leaps.

The Moment It Clicked Once the initial spark was lit, Michelle’s curiosity snowballed. For Early-Career Scientists: Your pivotal moment might not feel like fireworks. For innovators and biotech strategists, stories like Michelle’s reveal how scientific leadership emerges For GPCR research, leaders like Michelle are showing what happens when we follow the signal all the way . 🎧 Listen to the full conversation with Michelle Halls on  The Dr.

This lesson asks a deceptively simple question: What if our molecules—not our targets—are limiting discovery Lesson:  The structure-response relationship is rarely linear — and observing the unexpected is part This reroutes discovery toward: Functionally selective ligands Better therapeutic windows More predictable Advances in formulation and delivery have overcome earlier pharmacokinetic limitations. Terry Kenakin, monthly AMA discussions, and on-demand access to a library of expert GPCR teaching sessions

Learners can study at their own pace, shape the curriculum, and join live monthly AMA sessions with Dr Anyone who joins Premium before these changes go live will be grandfathered at their current rate , as Whether you’d like to partner, teach, share tools and technologies, or simply offer feedback , your input From free resources like the podcast and blog to our Premium ecosystem and Foundry initiatives, our mission Related Links 🔗 Explore Terry’s Pharmacology Corner → TerryKenakin.com 📧 Connect with us →   Hello@

(affinity, efficacy, co-operativity) Determining mechanisms of action for new GPCR ligands Elements and effective GPCR discovery Master advanced applications: Using new cellular assays to analyze GPCR ligand behavior Predicting activity and in vivo target coverage with real-time kinetics Discovering new ligands human G protein-coupled receptor biology and pharmacology Industry News Muscarinic drugs breathe new life into schizophrenia pipeline GPCR Dynamics Reveal Mechanisms for Drug Discovery DMS: Linking Protein

Raised in a small town in southern Sweden, he had never met anyone with a PhD and had little exposure foods, he saw life sciences as a field full of promise. Predictive GPCR-Ligand Modeling Carlsson's work quickly shifted from curiosity to impact. work inevitably reaches a point where novel, non-commercial ligands are needed. Looking for more insights like this? The Dr.

GPCR Premium: Sneak Peek Industry insights:  Confo VLAIO grant; Skye CB1 Ph2 miss; Chugai CT-388 in-license 🎥  Live AMA with Dr. Kenakin — October 30, 12 PM EST   Join Dr. Kenakin live and bring the questions that keep you thinking. Know the limits —where AI helps and where it still overpromises. Listen to the episode ➤ Why Dr.

De Graaf for their excellent work on Comparative Study of Allosteric GPCR Binding Sites and Their Ligandability Heterodimerization when Expressed Heterologously in Saccharomyces cerevisiae The beta 2 adrenergic receptor cross-linked signaling-competent receptors GPCRs in Neuroscience Astrocyte Gi-GPCR signaling corrects compulsive-like dendritic cells Methods & Updates in GPCR Research Generation of CRISPR/Cas9 modified human iPSC line Molecular Insights into GPCR Function Comparative Study of Allosteric GPCR Binding Sites and Their Ligandability

groundbreaking work on Positive allosteric modulation of a GPCR ternary complex Unlock Your Learning: Limited Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work  in a developing UK announced the winners of its Transforming Cancer Therapeutics grant, which focuses on developing life-changing for schizophrenia Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing GPCR ternary complex GPCR Binders, Drugs, and more Progress on the development of Class A GPCR-biased ligands

They’re kinetic game-changers —compounds that rewrite the relationship between ligand , receptor , and pharmacologic terms. ✅ Foresight to exploit persistent binding  without triggering long-term toxic liabilities But it also means new liability surfaces : persistent effects can’t be simply “washed out” when things That’s the hidden liability beneath the kinetic edge. Irreversible binding isn’t a magic bullet. A growing on-demand library  where enzyme inhibition, activation, and metabolism are demystified with

eyJ1IjoiaHR0cHM6Ly9kb2kub3JnLzEwLjExMTEvYnBoLjcwMDcyIiwiciI6ImUyZGZlOTFjLTM5YzgtNDA5Yi04NTUyLWI5NjUwNGRlNzc4MyIsIm0iOiJtYWlsX2xwIiwiYyI6IjAwMDAwMDAwLTAwMDAtMDAwMC0wMDAwLTAwMDAwMDAwMDAwMCJ9 The B2D consortium revives biodiversity as a source for selective GPCR ligands

Maria Majellaro, highlighting their fluorescent ligand tools for live-cell GPCR assays.   industry side, Novo Nordisk, Septerna, and Deep Apple advance billion-dollar GPCR programs, while Eli Lilly GLP-1R/GIPR biased agonism enhances metabolic outcomes Ghrelin receptor flips D2 signaling without a ligand It emphasizes scaffold selection, linker optimization, and assay compatibility to enhance target binding Constitutive ghrelin receptor activity, not dimerization or ligand binding —reverses dopamine D2 signaling

Eric Trinquet, a veteran innovator behind functional GPCR assays like HTRF and IP-One, believes rigid and Tag-lite. Instead of chasing linear progress, Eric encourages young scientists to stay playful longer—embracing Dual control: not just brightness but fluorescence lifetime, with drastic shifts as pH drops. GPCR X Revvity Collaboration ⸻ Want more like this? 👉 Join the Dr.

Premium gives you the full context, links, and our editorial notes—this is just the teaser. Whether you’re designing a ligand, optimizing ADME, or predicting PK, enzyme inhibition defines what 🎥 Live AMA with Dr. Kenakin live. Each session shapes next month’s lessons—so your challenges guide the content. built for busy scientists A voice in future course topics Fresh, weekly content that stays relevant Live